Side-by-side · Research reference

AdipotidevsHexarelin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED15/49 cited

BPhase 1HUMAN-REVIEWED19/45 cited

Adipotide

Pro-apoptotic Vascular-Targeting Peptide · Preclinical Only

PreclinicalStatus

PHB1TargetHossen 2013

ApoptosisMechanismHossen 2013

IV · Systemic · Preclinical Protocols OnlyHossen 2013

Hexarelin

Hexapeptide GHRP · Cardio-tropic

100–200 mcgPer doseSmith 1996

Phase 1Evidence levelGhigo 1997

~70 minHalf-lifeSemenistaya 2010

SQ · Multiple sites · 1–3×/day

01Mechanism of Action

Parameter

Adipotide

Hexarelin

Primary target

Prohibitin-1 (PHB1) on adipose vasculature endotheliumHossen 2013

Ghrelin receptor (GHS-R1a) + cardiac CD36Smith 1996 Ghigo 1997

Pathway

CKGGRAKDC domain binds PHB1 → Peptide internalisation → D(KLAKLAK)₂ mitochondrial membrane disruption

GHS-R1a → Gαq → Ca²⁺ → GH release. CD36 engagement → direct cardio-tropic actionGhigo 1997

Downstream effect

Endothelial apoptosis → Adipose vascular collapse → Adipocyte involution → Weight loss

Strong GH pulse + IGF-1 elevation; cardio-protective effects in animal MI modelsGhigo 1997

Feedback intact?

N/A — Direct apoptotic mechanism, non-hormonal

Yes initially; tachyphylaxis with chronic useGhigo 1997

Origin

Synthetic bioconjugate: PHB1-targeting homing peptide + pro-apoptotic KLA sequence

Synthetic hexapeptide His-D-2-Methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂Smith 1996

Antibody development

—

02Dosage Protocols

Parameter

Adipotide

Hexarelin

Animal dose (mouse)

Low dose (not specified in abstract)Hossen 2013

Systemic injection in diet-induced obesity (DIO) models.Hossen 2013

—

Route

Intravenous (systemic injection)

—

Frequency

Not specified in available data

1–2× per day max (tachyphylaxis with chronic 3× daily)

Evidence basis

Preclinical animal models only

Phase 1 / Phase 2 trialsSmith 1996 Ghigo 1997

Human data

None — no clinical trials reported

—

Standard dose

—

100–200 mcg per injectionSmith 1996

Lower / starter dose

—

50 mcg per dose

Duration

—

4–8 weeks on / 4–8 weeks off (tachyphylaxis mitigation)

Reconstitution

—

Bacteriostatic water

Timing

—

Pre-sleep + fasted preferred

Half-life

—

~70 minSemenistaya 2010

03Metabolic / Fat Loss Evidence

Parameter

Adipotide

Hexarelin

Primary fat target

White adipose tissue (all depots)

—

Mechanism

Vascular apoptosis → adipose blood supply collapse → adipocyte deathHossen 2013

—

Body weight reduction

Significant reduction in DIO miceHossen 2013

Absolute values not provided in abstract.

—

Leptin levels

Significant decrease

Parallel to adipose mass reduction.

—

Effect on adipocytes

Antiobesity effect on dysfunctional adipose cells (adipocytes + macrophages)Hossen 2013

—

Ectopic fat

Reduction in ectopic fat depositionHossen 2013

Marker of dysfunctional adipose tissue / metabolic syndrome.

—

Species tested

Obese rhesus monkeys, DIO mice

—

Human translation

Unknown — no clinical trials

—

04Side Effects & Safety

Parameter

Adipotide

Hexarelin

Safety profile

Unknown — preclinical data only

—

Vascular selectivity

Targets adipose vasculature; off-target vascular effects unknown

—

Apoptotic mechanism risk

Pro-apoptotic payload may affect unintended tissues if selectivity incomplete

—

Kidney / liver toxicity

Not reported in available data

—

Immunogenicity

Not assessed in available data

—

Cortisol elevation

—

Modest at high dosesGhigo 1997

Prolactin elevation

—

Modest at high dosesGhigo 1997

Hunger

—

Strong appetite increase via ghrelin agonism

Tachyphylaxis

—

Receptor desensitisation with chronic dosingGhigo 1997

Cardiac effects

—

Direct cardio-tropic; potential benefit in MI but unstudied in humansGhigo 1997

IGF-1 elevation

—

Strong; monitor with chronic high-dose use

Cancer risk

—

Contraindicated in active malignancy (GH/IGF-1 axis)

Pregnancy / OB

—

Avoid

Absolute Contraindications

Adipotide

·Human use — not approved, no clinical safety data

Hexarelin

·Active malignancy
·Pregnancy / breastfeeding
·Disrupted hypothalamic-pituitary axis

Relative Contraindications

Adipotide

·Any condition requiring intact adipose-tissue vascularisation

Hexarelin

·Untreated diabetes
·Severe hyperprolactinemia

05Administration Protocol

Parameter

Adipotide

Hexarelin

1. Route

Intravenous injection (systemic) in preclinical models. No human protocols exist.

Add 2 mL bacteriostatic water to 5 mg vial → 2.5 mg/mL = 250 mcg per 0.1 mL.

2. Formulation

Bioconjugate peptide. May also be encapsulated in nanoparticles (prohibitin-targeted nanoparticle formulation, KLA-PTNP, showed superior efficacy vs. free bioconjugate in mice).Hossen 2013

SQ — abdomen or thigh. Rotate sites.

3. Preclinical dosing

Low-dose systemic injection (exact dosing not specified in available abstract). Frequency and duration not detailed.Hossen 2013

Pre-sleep + fasted preferred. Cycle on/off to avoid tachyphylaxis.

4. Storage

Not specified — likely requires peptide-grade lyophilised storage and reconstitution.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

5. Needle

—

29–31G, 4–8 mm insulin syringe.

06Stack Synergy

Adipotide

— no documented stacks

Hexarelin

+ CJC-1295 (no DAC)

Strong

View CJC-1295 (no DAC) →

Hexarelin (GHRP) + CJC-1295-no-DAC (GHRH analogue) is the higher-amplitude variant of the standard GHRH+GHRP stack. Hexarelin produces a stronger pulse than ipamorelin but with cortisol + prolactin signal — choose this stack for maximum GH amplitude when side-effect tolerance is acceptable. Cycle aggressively.

Hexarelin: 100 mcg SQ · pre-sleep
CJC-1295 (no DAC): 100 mcg SQ · same injection
Primary benefit: Maximum GH pulse amplitude (with side-effect signal)

Smith 1996 Teichman 2006